Dacomitinib (Dacomitinib) Standard Usage, Dosage and Taking Guidelines

Dacomitinib is an oral small molecule tyrosine kinase inhibitor mainly used to treat patients with non-small cell lung cancer (NSCLC) carrying EGFR gene mutations. Its mechanism of action is to irreversibly bind and inhibit the tyrosine kinase activity of EGFR, blocking the signal transduction of tumor cells, thereby inhibiting the proliferation and growth of tumor cells. Dacomitinib, as a first-line treatment, provides an effective targeted therapy option for many patients with EGFR mutation-positive tumors.

The standard dosage of dacomitinib is usually once daily, with the recommended dose being 45 mg. Patients should strictly follow the doctor's instructions and should not adjust the dosage on their own. In order to ensure the absorption effect of the drug, it is recommended that patients take it on an empty stomach, preferably one hour before or two hours after a meal. Tablets should be swallowed whole and avoid chewing, crushing or splitting to ensure stable release and efficacy of the drug.

During treatment, patients may experience some common side effects, such as rash, diarrhea, stomatitis, and onychomycosis. When side effects occur, patients should promptly inform their doctor, who may adjust the dose or provide corresponding supportive treatment according to the specific situation. Serious side effects, such as lung inflammation or abnormal liver function, require immediate discontinuation of the drug and further examination and treatment. Do not stop taking the medication or adjust the dose on your own, as this may affect the therapeutic effect.

Finally, during dacomitinib treatment, relevant examinations need to be carried out regularly, including monitoring of liver function, kidney function and pulmonary function, to ensure that patients take the drug safely. In addition, patients should avoid coadministration with drugs that affect hepatic enzymes to reduce the risk of drug interactions. Maintaining good living habits and regular follow-up visits are important links to ensure the smooth progress of treatment. Patients should work closely with their doctors to ensure the best results from dacomitinib treatment.

Reference materials:https://www.drugs.com